The Kærtor Foundation will govern the program by applying its own methodology for the preliminary analysis and prioritized classification of the Expressions of Interest received, based on the level of innovation and the stage of the development.
A pipeline of prioritized Expressions of Interest will be created on the basis of evaluations by three committees
- Scientific, led by the Kærtor Foundation.
- Intellectual property, led by Kærtor.
- Industrial, led by the pharmaceutical company Janssen, which will bring its experience in the field of drug discovery to select the Expressions of Interest showing the strongest potential to provide new medicines for patients. This committee includes Janssen and two other Johnson & Johnson group organizations: Discovery Sciences and Johnson & Johnson Innovation.
The Program Steering Committee will subsequently select expressions of interest for incubation.
Kærtor may also select other programs that do not form part of those chosen by the Program Steering Committee for independent incubation.